CAMBRIDGE, Mass., Nov. 3, 2018 – Disarm Therapeutics, a biotechnology company creating a new class of disease-modifying therapeutics for patients with axonal degeneration, a central driver of neurological disease, today announced data demonstrating that genetic inhibition of SARM1 prevents axonal degeneration in the central, ocular and peripheral nervous systems.
Disarm Therapeutics

Carrick Therapeutics, a biopharmaceutical company focusing on the innovative research and development of transformative oncology medicines, has today announced that it has licensed exclusive worldwide rights to develop and commercialise BTG945, now CT900, an investigational targeted ovarian cancer drug, from the global specialist healthcare company BTG plc ("BTG",LSE: BTG).

PR Newswire

BOSTON--(BUSINESS WIRE)--Cerevance, a clinical-stage drug discovery and development company focused on brain diseases, today announced the start of dosing in a Phase I first-in-human clinical trial of CVN424, an oral compound being developed for symptomatic treatment of Parkinson’s disease. 

Cardiology devices as a category fared well in the Medicare inpatient rule for fiscal 2019, but Claret Medical Inc. of Santa Rosa, Calif., was perhaps the biggest winner. The company snared a new technology add-on payment for its Sentinel embolic filter device for use during aortic valve procedures, which in turn sparked an additional $50 million payment from Boston Scientific in its acquisition of Claret in a deal announced only two weeks ago.
BioWorld Medtech
MARLBOROUGH, Mass., July 20, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has signed an agreement to acquire Claret Medical, Inc., a privately-held company that has developed and commercialized the Sentinel® Cerebral Embolic Protection System.
Boston Scientific
As an associate professor at The Jackson Laboratory, Kevin Mills zeroed in on the supporting role that the RAD51 protein played in repairing the DNA damage caused by elevated levels of activation-induced cytidine deaminase, or AID.
Endpoints News
The rapid growth of cancer cells actually damages them, leading them to rely on internal repair mechanisms. Scientists are finding ways to disrupt these repair features to fight the disease, and their research is leading to a growing crop of startups. Among them: Cambridge, MA-based Cyteir Therapeutics, which has just raised $29 million from Venrock, Celgene, and others.
FIRE1 has raised $50 million to advance remote heart monitoring technology. The device is designed to enable the remote monitoring of heart failure patients and thereby improve outcomes in a group that suffers from persistently high mortality rates.
Fierce Biotech